- Photrexa CXL kits biodegradable packaging unable to maintain regulatorily specified temperatures
Glaukos Corporation
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Glaukos Corporation disclosed greenhouse gas emissions of 2.7K tCO2e/year (Scope 1 and 2). By scope: Scope 1: 575.4 tCO2e/year; Scope 2: 2.2K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
2.7K tCO2e/year (Scope 1 and 2)
2023
Renewable Energy
58%
of total energy
Water Usage
1.1M gallons/year
2023
Waste
15.3K pounds/year (Hazardous)
2023
Energy Use
8.9M kWh/year
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 575.4 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 2.2K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 2.7K tCO2e/year (Scope 1 and 2) |
| 2022 | 1.9K mt |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced emissions associated with flights amounting to a total CO2 GHG emission estimated at 1,286 tons due to a second product distribution site, resulting in reduced shipping costs and elimination of 6.4 million air miles
- Obtained ISO Certification for Burlington site, signifying our commitment to environmental management system standards
🎯 Climate & Sustainability Targets
🔜 Short-term
- Help >5,000 patients navigate their keratoconus treatment journey by 2024
- Establish process to make iDose accessible to underserved communities via the iDose Your Dose global program by 2024
- Provide a comprehensive range of services to U.S. patients and caregivers enrolled through a healthcare provider or self-enrolled to support the critical phase of early decision-making about their keratoconus or glaucoma care by 2025
- Develop a team of Patient Ambassadors to educate U.S. patient and advocacy organizations by 2027
- Conduct engineering evaluation of conversion to biodegradable Corneal Health packaging in 2024
📅 Medium-term
- By 2025, formally track alignment of the information security program to relevant components of the NIST security framework based upon risk to Glaukos and industry best practices
- By 2030, surpass 10,000 cumulative stent donations and 150 recipient organizations
🌱 ESG Focus Areas
GovernanceProductsSocialEnvironmental